# Lumicell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lumicell

- Industry: Medical Devices & Equipment
- Headquarters: Newton, US
- Website: www.lumicell.com
- Total disclosed funding: $31M
- Latest round: Series C (Dec 7, 2017)
- Investors on record: 3

## About

Lumicell Inc. specializes in enhancing cancer surgery through innovative fluorescence imaging technology, providing tools that assist surgeons in accurately identifying and removing cancerous tissues during procedures.Founded in 2009 in Newton, US, Lumicell Inc. is dedicated to developing advanced imaging solutions for cancer surgeries. The company has completed a total of 6 deals and recently raised USD 20.00 mn in funding. Andrey Zarur, the founder, has a history of entrepreneurial ventures, and the current CEO is Kevin Hershberger.Lumicell focuses on revolutionizing cancer surgery through its advanced fluorescence imaging technology, primarily encapsulated in its flagship products, LUMISIGHT™ (pegulicianine) and the LumiSystem™. These products are designed to provide real-time visualization of residual cancer during surgical procedures, particularly in lumpectomy surgeries for breast cancer patients. The LUMISIGHT™ agent, when administered, binds to cancerous tissues, allowing surgeons to distinguish between healthy and malignant cells with enhanced precision. This capability aims to reduce the likelihood of cancer recurrence by ensuring that all cancerous tissues are removed during initial surgery. The company’s offerings are targeted toward healthcare providers, including hospitals and surgical centers, in the United States and are anticipated to extend to other regions as regulatory approvals are obtained.Lumicell generates revenue primarily through the sale of its innovative fluorescence imaging products, with a focus on establishing partnerships and direct sales to healthcare institutions. The pricing structure for its flagship products, LUMISIGHT™ and the LumiSystem™, is designed to align with the economic considerations of hospitals and surgical centers seeking to improve surgical outcomes and reduce postoperative complications for patients. Transactions typically involve direct sales agreements with hospitals, where the products are purchased for integration into surgical protocols. By offering advanced imaging solutions that enhance the efficiency and effectiveness of cancer surgeries, Lumicell positions itself as a critical partner in the healthcare ecosystem, facilitating better patient outcomes while driving its revenue model based on B2B interactions within the medical technology sector.Lumicell Inc. is focused on expanding its product portfolio with new developments aimed at improving surgical imaging capabilities. The company is actively pursuing market expansion into additional healthcare systems beyond the United States, with plans to penetrate European markets by 2025. The recent venture funding of USD 20.00 mn from Kinled Holding will be utilized to support these product launches and geographical expansions.

## Funding rounds

- Series C, Dec 7, 2017, $29M — LaunchCapital, BlueIO
- Series A, May 18, 2011, $2.7M — Kodiak Venture Partners

## Investors

- Kodiak Venture Partners (https://capitalatlas.ai/funds/kodiak-venture-partners) — Series A
- LaunchCapital (https://capitalatlas.ai/funds/launchcapital) — Series C
- BlueIO (https://capitalatlas.ai/funds/blueio) — Series C